Vol. 3 No. 1 (2026): January - March
101-108
2026-03-30
Open Access

Application of GLP-1 Receptor Agonists in Cardiorenometabolic Syndrome

E. Nomozov
Nigora Z.Srojidinova
https://doi.org/10.70626/cardiouz-2026-3-00082

Received: 2026-07-08

Published: 2026-03-30

PDF (Uzbek)
Crossmark Crossmark

Abstract

Cardiorenometabolic syndrome (CRMS) is one of the most important challenges in modern medicine and is considered a leading cause of morbidity and mortality worldwide. Major randomized clinical trials conducted over the past five years — SELECT (2023), FLOW (2024), and STEP-HFpEF (2023) — have provided fundamentally new insights into the cardiovascular and renal protective mechanisms of GLP-1 receptor agonists (GLP-1 RAs), particularly semaglutide. The effects of GLP-1 RAs extend beyond glycemic control and involve a multifaceted biological network targeting endothelial dysfunction, oxidative stress, NF-κB–mediated inflammation, activation of the renin–angiotensin–aldosterone system (RAAS), intraglomerular hyperfiltration, and visceral adiposity. Current clinical and mechanistic evidence provides sufficient rationale to consider this drug class as one of the key pillars of future CRMS management.

Keywords

List of references

  1. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. https://doi.org/ 10.1161/CIR.0000000000001184.

  2. Khan SS, Ning H, Wilkins JT, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Circulation. 2023;148(20):1636–1664. https://doi.org/10.1161/CIR.0000000000001186.

  3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–1844. https://doi.org/10.1056/NEJMoa1607141.

  4. Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024;263(1). https://doi.org/10.1530/ JOE-24-0046.

  5. Yang HM. GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies. J Clin Med. 2025;14(19):6758. https://doi.org/10.3390/jcm14196758.

  6. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740–756. https://doi.org/10.1016/j.cmet.2018.03.001.

  7. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. https://doi.org/10.1021/acs.jmedchem. 5b00726.

  8. Menghini R, Casagrande V, Rizza S, Federici M. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? Acta Diabetol. 2023;60(11):1471–1478. https://doi.org/10.1007/s00592-023-02124-w.

  9. Rajagopal D, Al Rashid S, Prasad M, Fareed M. Unveiling the Potential Role of GLP-1 Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems. Cureus. 2024;16(7):e65910. https://doi.org/10.7759/cureus.65910.

  10. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301(2):F355–F363. https://doi.org/10.1152/ajprenal.00729.2010.

  11. Nespoux J, Vallon V. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Acta Diabetol. 2023;61:1–14. https://doi.org/10.1007/s00592-023-02171-3.

  12. Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front Pharmacol. 2020;11:967. https://doi.org/10.3389/fphar.2020.00967.

  13. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https://doi.org/10.1186/s12933-021-01366-8.

  14. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563.

  15. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069–1084. https://doi.org/10.1056/ NEJMoa2306963.

  16. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390:1394–1407. https://doi.org/10.1056/NEJMoa2313917.

  17. Tang H, Lu Y, Zhang B, et al. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes Obes Metab. 2025. https://doi.org/10.1111/dom.70054.

  18. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121. https://doi.org/10.1056/NEJMoa2403347.

  19. Mahaffey KW, Tuttle KR, Arici M, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2024. https://doi.org/10.1093/eurheartj/ ehae613.

  20. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058–2066. https://doi.org/10.1038/s4 1591-024-03015-5.

  21. Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1379189. https://doi.org/10.3389/fcvm.2024.1379189.

  22. Fathulla HH, Al-Auqbi TFM. GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes. Biomedicines. 2025;13(4):939. https://doi.org/10.3390/biomedicines13040939.

  23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018.

  24. American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216–S249.

  25. American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–S265.

  26. Rossing P, Tuttle KR, Perkovic V, et al. Semaglutide and concurrent SGLT2 inhibitor use in people with type 2 diabetes and chronic kidney disease: a pre-specified analysis of the FLOW trial. Lancet Diabetes Endocrinol. 2025;13(2):119–130. https://doi.org/10.1016/S2213-8587(24)00335-6.

  27. Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024;331(21):1858–1860. https://doi.org/10.1 001/jama.2024.6892.

  28. International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Brussels: International Diabetes Federation; 2025. https://diabetesatlas.org.

  29. GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025. https://doi.org/10.1016/S0140-6736(25)01853-7.

  30. Alieva A, Khaydarova F, Rakhimova G, Ismailov S, et al. Epidemiology of diabetes mellitus and prediabetes in Uzbekistan: screening results. Tashkent; 2018.

About the Authors

E. Nomozov
cardiologist0109@gmail.com
Republican Specialized Scientific and Practical Medical Center of Cardiology

PHD student

Nigora Z.Srojidinova
nigora5505@gmail.com
Republican Specialized Scientific and Practical Medical Center of Cardiology

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Application of GLP-1 Receptor Agonists in Cardiorenometabolic Syndrome (E. Nomozov & N. Srojidinova, Trans.). (2026). CARDIOLOGY OF UZBEKISTAN, 3(1), 101-108. https://doi.org/10.70626/cardiouz-2026-3-00082
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.

ISSN 3060-4850 (Print)